Krsnaa Diagnostics to issue 16.21 Lakh Warrants to Promoter Group for ₹91.75 Cr
Krsnaa Diagnostics will issue up to 16.21 lakh warrants to its Promoter and Promoter Group for ₹91.75 crore. The warrants are convertible into equity shares at ₹566 each. Funds will be used for capital expenditure on diagnostic equipment and acquisitions. Shareholders will vote via e-voting from August 19 to September 17, 2026.
The preferential issue of warrants will increase the equity base and provide funds for strategic growth, which can have a medium-term positive impact on the company's financial performance and expansion plans. The total amount raised is significant relative to the company's size.
The company is raising capital through a preferential issue to its promoter group, which is generally viewed positively as it indicates promoter confidence and provides funds for growth initiatives like capital expenditure and acquisitions.
Krsnaa Diagnostics Limited has announced the issuance of up to 16,21,000 warrants convertible into equity shares on a preferential basis to the Promoter and Promoter Group. The total issue size amounts to ₹91.75 crore (₹91,74,86,000).
The warrants will be issued at a price of ₹566 each, with each warrant convertible into one equity share of face value ₹5 at an exercise price of ₹566 per share (including a premium of ₹561).
Shareholders will vote on this proposal through postal ballot via remote e-voting. The e-voting period will commence on August 19, 2026, at 09:00 Hrs (IST) and conclude on September 17, 2026, at 17:00 Hrs (IST).
Proceeds from this preferential issue will be utilized for capital expenditure, including the purchase and installation of diagnostic equipment like CT Scanners and MRI machines (₹68.81 crore), and for funding acquisitions (₹22.94 crore).
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.